ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

ASCO 2026: Pfizer Posts Wins Across Three Cancers as Bigger Catalysts Loom

Pfizer used ASCO 2026 to reinforce its oncology credentials across lung, colorectal and prostate cancer with late-breaking data that strengthen the commercial positioning of approved assets. Yet the New York pharma giant's most consequential catalysts remain ahead, making this year's conference more of a staging ground than a finish line. Structured plan for ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come.

Key Takeaways

• Lobrena's seven-year CROWN data in ALK-positive NSCLC showed a striking durability signal, with 55% of patients alive without progression at seven years versus 3% in the control arm — a benchmark that could further entrench the drug as first-line standard of care.
• Braftovi's BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer demonstrated meaningful progression-free survival improvement when combined with FOLFIRI, building on the FDA's February full approval in first-line mCRC and supporting label expansion into additional chemo backbones.
• Talzenna showed PFS benefit in metastatic prostate cancer, reinforcing Pfizer's PARP inhibitor as a competitive option in a crowded but growing biomarker-defined segment.
• The biggest investor catalysts are still to come. Leerink Partners called this "not a big ASCO year from the vantage-point of stock-moving data," with the most anticipated Pfizer readouts expected later in 2026.
• The Innovent Biologics collaboration signals Pfizer's intent to backfill its oncology pipeline with China-sourced assets, several of which were previewed at ASCO.

What Happened at ASCO 2026?

Pfizer arrived at ASCO 2026 with more than 40 abstracts, three late-breaking presentations and several oral sessions — a broad but strategically curated oncology showing. The company presented updated Phase 3 data across three approved franchises, each designed to deepen the evidence base for earlier-line or expanded use.

The headline late-breaker was the seven-year update from the CROWN trial, comparing Pfizer's third-generation ALK inhibitor Lobrena (lorlatinib) against the earlier-generation Xalkori (crizotinib) in previously untreated, ALK-positive advanced non-small cell lung cancer. At seven years, the seven-year progression-free survival rate was 55% for Lobrena versus just 3% for the control arm. Overall survival data are not yet mature; Pfizer's chief development officer of oncology, Johanna Bendell, said the company expects that readout within the next year.

Sarah Goldberg, chief of thoracic oncology at Yale Cancer Center, called the durability "unlike any trial we've seen," adding that the longer-term follow-up makes a more convincing case for Lobrena as the first-line choice in this population.

In colorectal cancer, Pfizer presented new results from the BREAKWATER trial, evaluating its BRAF inhibitor Braftovi (encorafenib) plus Eli Lilly's Erbitux and the FOLFIRI chemotherapy regimen in previously untreated patients with BRAF V600E-mutant metastatic colorectal cancer. The Braftovi/FOLFIRI combination demonstrated meaningful improvement in progression-free survival. These data complement earlier BREAKWATER results using mFOLFOX6 as the chemo backbone and build on the FDA's February full approval of Braftovi in first-line metastatic colorectal cancer.

Pfizer also shared data for Talzenna (talazoparib) in metastatic prostate cancer, where the PARP inhibitor gave patients a significantly better chance of survival without disease progression. The results reinforce Talzenna's position in the growing biomarker-defined prostate cancer segment, though specific numeric data from the ASCO presentation were not detailed in the available reporting.

Beyond the approved portfolio, Pfizer previewed early-stage assets emerging from its recently announced collaboration with China's Innovent Biologics — a deal covering 12 oncology candidates that Bendell said reflects the company's intent to "go big and make impact."

What Does This Mean for Pfizer's Oncology Franchise?

For BD teams and competitive intelligence groups, the ASCO data serve a dual purpose: they validate Pfizer's existing oncology franchises while signaling where the company is placing its next bets.

The Lobrena seven-year CROWN update is commercially significant because it addresses a key question that has followed ALK inhibitors for years — durability. A 55% PFS rate at seven years in first-line ALK-positive NSCLC is a benchmark that competitors will struggle to match without similarly mature follow-up. For Pfizer, the data strengthen Lobrena's formulary positioning and provide a compelling narrative for global market access negotiations, particularly in health technology assessment environments that weight long-term outcomes heavily. The pending OS readout, expected within 12 months, represents the next major catalyst for the franchise.

Braftovi's BREAKWATER expansion into the FOLFIRI backbone gives Pfizer and its partners a more complete data package across the two standard chemotherapy regimens used in metastatic colorectal cancer. This matters commercially because it allows the Braftovi-Erbitux combination to compete for a larger share of the BRAF V600E-mutant mCRC market regardless of which chemo backbone a physician prefers. The February full approval already de-risked the regulatory pathway; the ASCO data now provide the clinical evidence to drive uptake.

Talzenna's prostate cancer showing comes at a time when the PARP inhibitor class is becoming increasingly competitive, with AstraZeneca/Merck's Lynparza and GSK's Zejula also vying for share in biomarker-selected prostate cancer. Pfizer will need to differentiate on safety, convenience and combination data — areas where the TALAPRO program is expected to generate further readouts later this year.

From a pipeline strategy perspective, the Innovent deal is arguably the most consequential near-term move. It is one of the largest China-originated oncology collaborations in recent memory and gives Pfizer access to a dozen early-stage candidates. The fact that several were previewed at ASCO suggests Pfizer is already integrating them into its development timeline. For analysts tracking Pfizer's late-stage pipeline, these assets represent optionality that could materialize as clinical data in 2027 and beyond.

Leerink's David Risinger framed the dynamic clearly: this was not a stock-moving ASCO for Pfizer, but the readouts ahead are what matter. Investors and BD teams should watch for the Lobrena overall survival data, further TALAPRO results and early signals from the Innovent collaboration as the primary catalysts through the second half of 2026.

What Should Investors Watch in the Second Half of 2026?

Key catalysts include: overall survival data from the Lobrena CROWN trial, expected within 12 months; additional TALAPRO program readouts for Talzenna in prostate cancer; early clinical data from assets sourced through the Innovent collaboration; and potential regulatory filings or label expansions for Braftovi in colorectal cancer. Leerink Partners has noted that these upcoming readouts are more consequential for Pfizer's stock than the ASCO 2026 presentations.

Frequently Asked Questions

Related profiles

• Pfizer

Related coverage

• ASCO 2026 Preview: Key Data and Trends in Cancer Research
• FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
• Advancing Bladder Cancer Care Through Education and Awareness